Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early rituximab intensification and rituximab maintenance with R-CHOP14 in elderly patients with diffuse large B-cell lymphoma
ISRCTN82286322Phase 3Completed
- Sponsor
- HOVON
- Start
- Aug 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone and 1 more in diffuse large B-cell lymphoma (DLBCL) (4 arms), sponsored by HOVON. Started Aug 2007; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN82286322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82286322.